Skip to main content
TipRanks
Go Ultimate75% OFF

Nuvation Bio (NUVB) Revenue by Type

933 Followers

Revenue by Type

Nuvation Bio reported revenue by type of $44.95M in Q3 2026, up 41.9% from Q2 2026 and up 242.6% year over year. The highest value was $83.23M in Q1 2026.

Breaks down revenue into sources such as product sales, licensing, collaboration and milestone payments, and grants, highlighting whether income is recurring or one-time. For clinical-stage Nuvation Bio, which likely has limited commercial sales, this reveals reliance on partnerships and milestone receipts to fund R&D, the timing risks to cash flow and runway, and how close the company is to generating steady product revenue.

$0.00$20.00M$40.00M$60.00M$80.00MMar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Product revenue has moved from essentially zero to the company’s primary, steadily growing income stream over the past year—a direct reflection of IBTROZI’s commercial momentum (first‑line uptake, patient stacking and durable benefit). Collaboration/license income remains lumpy and milestone-driven, so overall top‑line stability now depends more on sustained product penetration than one‑off deals. That reduces reliance on episodic license spikes but elevates sensitivity to gross‑to‑net pressures, high SG&A/R&D spend and payer/testing dynamics; recent financing improves runway but introduces dilution tradeoffs.

NUVB Revenue by Type

PeriodProductCollaboration & License AgreementsTotal
Q3 2026Sep 30, 2026$27.46M$17.49M$44.95M
Q2 2026Jun 30, 2026$23.19M$8.49M$31.69M
Q1 2026Mar 31, 2026$18.51M$64.72M$83.23M
Q4 2025Dec 31, 2025$15.70M$26.16M$41.87M
Q3 2025Sep 30, 2025$7.72M$5.40M$13.12M
Q2 2025Jun 30, 2025$1.24M$3.60M$4.83M
Q1 2025Mar 31, 2025$0.00$3.08M$3.08M
Q4 2024Dec 31, 2024$0.00$5.71M$5.71M
Q3 2024Sep 30, 2024$0.00$727.00K$727.00K
Q2 2024Jun 30, 2024$0.00$1.44M$1.44M
Q1 2024Mar 31, 2024$0.00$0.00$0.00

Related KPIs